These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

749 related items for PubMed ID: 18585385

  • 1. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b.
    Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL.
    Gastroenterology; 2008 Aug; 135(2):459-67. PubMed ID: 18585385
    [Abstract] [Full Text] [Related]

  • 2. Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients.
    Buster EH, Flink HJ, Simsek H, Heathcote EJ, Sharmila S, Kitis GE, Gerken G, Buti M, de Vries RA, Verhey E, Hansen BE, Janssen HL.
    Am J Gastroenterol; 2009 Oct; 104(10):2449-57. PubMed ID: 19584831
    [Abstract] [Full Text] [Related]

  • 3. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.
    Antivir Ther; 2012 Oct; 17(1):9-17. PubMed ID: 22267464
    [Abstract] [Full Text] [Related]

  • 4. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL.
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [Abstract] [Full Text] [Related]

  • 5. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
    Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL.
    Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
    [Abstract] [Full Text] [Related]

  • 6. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N, Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group.
    N Engl J Med; 2005 Jun 30; 352(26):2682-95. PubMed ID: 15987917
    [Abstract] [Full Text] [Related]

  • 7. Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.
    Wiegand J, Brosteanu O, Kullig U, Wiese M, Berr F, Maier M, Tillmann HL, Schiefke I.
    Z Gastroenterol; 2011 Nov 30; 49(11):1463-9. PubMed ID: 22069045
    [Abstract] [Full Text] [Related]

  • 8. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype.
    Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL, HBV 99-01 Study Group.
    Am J Gastroenterol; 2006 Feb 30; 101(2):297-303. PubMed ID: 16454834
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z.
    Eur J Gastroenterol Hepatol; 2013 Oct 30; 25(10):1165-9. PubMed ID: 23571612
    [Abstract] [Full Text] [Related]

  • 10. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, Pas SD, Hansen BE, Janssen HL.
    Hepatology; 2012 Jul 30; 56(1):67-75. PubMed ID: 22307831
    [Abstract] [Full Text] [Related]

  • 11. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H, Yang RF, Wei L.
    J Gastroenterol Hepatol; 2010 Sep 30; 25(9):1498-506. PubMed ID: 20796146
    [Abstract] [Full Text] [Related]

  • 12. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
    Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P.
    Hepatology; 2009 Apr 30; 49(4):1141-50. PubMed ID: 19338056
    [Abstract] [Full Text] [Related]

  • 13. Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders.
    Rijckborst V, Ferenci P, Akdogan M, Pinarbasi B, ter Borg MJ, Simon K, Flisiak R, Akarca US, Raptopoulou-Gigi M, Verhey E, van Vuuren AJ, Boucher CA, Hansen BE, Janssen HL, PARC Study Group.
    Eur J Gastroenterol Hepatol; 2012 Sep 30; 24(9):1012-9. PubMed ID: 22668876
    [Abstract] [Full Text] [Related]

  • 14. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y.
    J Clin Virol; 2009 Oct 30; 46(2):117-23. PubMed ID: 19651540
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
    Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN.
    J Gastroenterol Hepatol; 2011 Mar 30; 26(3):461-8. PubMed ID: 21332543
    [Abstract] [Full Text] [Related]

  • 17. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
    Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, Dijkgraaf MG, Molenkamp R, Jansen PL, Koot M, Rijckborst V, Janssen HL, Beld MG, Reesink HW.
    Antivir Ther; 2013 Mar 30; 18(7):895-904. PubMed ID: 23639931
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
    Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, Rothe V, Regep L, Bonino F.
    J Hepatol; 2013 Dec 30; 59(6):1153-9. PubMed ID: 23872601
    [Abstract] [Full Text] [Related]

  • 20. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.
    J Dig Dis; 2013 Aug 30; 14(8):446-50. PubMed ID: 23615131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.